Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	positive regulation of endoplasmic reticulum calcium ion concentration	ATP2A1 ATP2A2	2.49e-05	3	60	2	GO:0032470
Domain	P-type_ATPase_IIA	ATP2A1 ATP2A2	2.55e-05	3	55	2	IPR005782
Domain	Hydrolase_3	ATP2A1 ATP2A2	3.77e-04	10	55	2	PF08282
Domain	-	ATP2A1 ATP2A2	9.95e-04	16	55	2	1.20.1110.10
Domain	ATPase_P-typ_TM_dom	ATP2A1 ATP2A2	9.95e-04	16	55	2	IPR023298
Domain	ATPase_P-typ_cation-transptr_C	ATP2A1 ATP2A2	1.13e-03	17	55	2	IPR006068
Domain	Cation_ATPase_C	ATP2A1 ATP2A2	1.13e-03	17	55	2	PF00689
Domain	Cation_ATPase_N	ATP2A1 ATP2A2	1.26e-03	18	55	2	PF00690
Domain	Cation_ATPase_N	ATP2A1 ATP2A2	1.26e-03	18	55	2	SM00831
Domain	ATPase_P-typ_cation-transptr_N	ATP2A1 ATP2A2	1.41e-03	19	55	2	IPR004014
Domain	PAS-assoc_C	ARNT KCNH2	2.25e-03	24	55	2	IPR000700
Domain	PAS	ARNT KCNH2	2.45e-03	25	55	2	PF00989
Domain	PAS_fold	ARNT KCNH2	2.45e-03	25	55	2	IPR013767
Domain	PAC	ARNT KCNH2	2.64e-03	26	55	2	IPR001610
Domain	PAC	ARNT KCNH2	2.64e-03	26	55	2	SM00086
Domain	PAC	ARNT KCNH2	2.64e-03	26	55	2	PS50113
Domain	FYVE	ZFYVE9 WDFY3	3.29e-03	29	55	2	PF01363
Domain	FYVE	ZFYVE9 WDFY3	3.29e-03	29	55	2	SM00064
Domain	-	ATP2A1 ATP2A2	3.99e-03	32	55	2	3.40.1110.10
Domain	-	ATP2A1 ATP2A2	3.99e-03	32	55	2	2.70.150.10
Domain	PAS	ARNT KCNH2	3.99e-03	32	55	2	SM00091
Domain	PAS	ARNT KCNH2	4.50e-03	34	55	2	IPR000014
Domain	Znf_FYVE-rel	ZFYVE9 WDFY3	4.50e-03	34	55	2	IPR017455
Domain	PAS	ARNT KCNH2	4.50e-03	34	55	2	PS50112
Domain	Ion_trans_dom	CACNA1B KCNH2 SCN3A	4.61e-03	114	55	3	IPR005821
Domain	Ion_trans	CACNA1B KCNH2 SCN3A	4.61e-03	114	55	3	PF00520
Domain	ATPase_P-typ_cyto_domN	ATP2A1 ATP2A2	4.76e-03	35	55	2	IPR023299
Domain	P_typ_ATPase	ATP2A1 ATP2A2	5.03e-03	36	55	2	IPR001757
Domain	ATPase_P-typ_P_site	ATP2A1 ATP2A2	5.03e-03	36	55	2	IPR018303
Domain	ATPASE_E1_E2	ATP2A1 ATP2A2	5.03e-03	36	55	2	PS00154
Domain	ATPase_P-typ_transduc_dom_A	ATP2A1 ATP2A2	5.31e-03	37	55	2	IPR008250
Domain	E1-E2_ATPase	ATP2A1 ATP2A2	5.31e-03	37	55	2	PF00122
Domain	Znf_FYVE	ZFYVE9 WDFY3	5.59e-03	38	55	2	IPR000306
Pubmed	Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca2+ ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice.	ATP2A1 ATP2A2	2.93e-06	2	60	2	12556521
Pubmed	Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent Cytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative Stress-induced Necrosis.	NR4A2 MAP3K5	2.93e-06	2	60	2	25752609
Pubmed	Atypical fast SERCA1a protein expression in slow myofibers and differential S-nitrosylation prevented by exercise during long term bed rest.	ATP2A1 ATP2A2	2.93e-06	2	60	2	19644701
Pubmed	Sarco(endo)plasmic reticulum Ca2+ ATPases (SERCA1 and -2) in human extraocular muscles.	ATP2A1 ATP2A2	2.93e-06	2	60	2	14638697
Pubmed	Sarco(endo)plasmic reticulum Ca2+ ATPase isoforms and their role in muscle physiology and pathology.	ATP2A1 ATP2A2	2.93e-06	2	60	2	10603953
Pubmed	Characterizing SERCA Function in Murine Skeletal Muscles after 35-37 Days of Spaceflight.	ATP2A1 ATP2A2	2.93e-06	2	60	2	34769190
Pubmed	Training induced decrease in oxygen cost of cycling is accompanied by down-regulation of SERCA expression in human vastus lateralis muscle.	ATP2A1 ATP2A2	2.93e-06	2	60	2	18953100
Pubmed	SERCA overexpression reduces hydroxyl radical injury in murine myocardium.	ATP2A1 ATP2A2	2.93e-06	2	60	2	16798816
Pubmed	Dissection of the functional differences between sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses.	ATP2A1 ATP2A2	2.93e-06	2	60	2	12975374
Pubmed	Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes.	FANCI FANCA	2.93e-06	2	60	2	14630800
Pubmed	Effect of chronic obstructive pulmonary disease on calcium pump ATPase expression in human diaphragm.	ATP2A1 ATP2A2	2.93e-06	2	60	2	15718407
Pubmed	SERCA1 truncated proteins unable to pump calcium reduce the endoplasmic reticulum calcium concentration and induce apoptosis.	ATP2A1 ATP2A2	2.93e-06	2	60	2	11402072
Pubmed	The ER-Localized Transmembrane Protein EPG-3/VMP1 Regulates SERCA Activity to Control ER-Isolation Membrane Contacts for Autophagosome Formation.	RB1CC1 ATP2A1 ATP2A2	7.34e-06	22	60	3	28890335
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	NR2C1 ZFHX4 RB1CC1 GTF3C6 PCM1 PRDM2 SPDL1	7.69e-06	418	60	7	34709266
Pubmed	Calpain 3 deficiency affects SERCA expression and function in the skeletal muscle.	ATP2A1 ATP2A2	8.77e-06	3	60	2	27055500
Pubmed	Sarcoplasmic reticulum Ca2+ ATPase pump is a major regulator of glucose transport in the healthy and diabetic heart.	ATP2A1 ATP2A2	8.77e-06	3	60	2	25615793
Pubmed	Phospholamban domain IB forms an interaction site with the loop between transmembrane helices M6 and M7 of sarco(endo)plasmic reticulum Ca2+ ATPases.	ATP2A1 ATP2A2	8.77e-06	3	60	2	11526231
Pubmed	The effects of the phenylalanine 256 to valine mutation on the sensitivity of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) Ca2+ pump isoforms 1, 2, and 3 to thapsigargin and other inhibitors.	ATP2A1 ATP2A2	8.77e-06	3	60	2	16410239
Pubmed	Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1.	ATP2A1 ATP2A2	8.77e-06	3	60	2	15972723
Pubmed	Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression.	ATP2A1 ATP2A2	8.77e-06	3	60	2	16754798
Pubmed	Coordinate regulation of SR Ca(2+)-ATPase and phospholamban expression in developing murine heart.	ATP2A1 ATP2A2	8.77e-06	3	60	2	9038922
Pubmed	Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1.	MAP3K5 FANCA	8.77e-06	3	60	2	16109778
Pubmed	Specific effects of endurance and sprint training on protein expression of calsequestrin and SERCA in mouse skeletal muscle.	ATP2A1 ATP2A2	8.77e-06	3	60	2	22466636
Pubmed	Genetic ablation of PI3Kγ results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels.	PIK3CG IL17RA	8.77e-06	3	60	2	22930133
Pubmed	BioID reveals an ATG9A interaction with ATG13-ATG101 in the degradation of p62/SQSTM1-ubiquitin clusters.	SYNRG ZFYVE9 WDFY3 RB1CC1 FAM135B USP33	9.92e-06	285	60	6	34369648
Pubmed	Network organization of the human autophagy system.	LRPPRC ARNT PIK3CG FANCI RB1CC1 CEP170B MAP3K5	1.03e-05	437	60	7	20562859
Pubmed	Sarcolipin inhibits polymerization of phospholamban to induce superinhibition of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs).	ATP2A1 ATP2A2	1.75e-05	4	60	2	12032137
Pubmed	The nongastric H+-K+-ATPases: molecular and functional properties.	ATP2A1 ATP2A2	1.75e-05	4	60	2	10362770
Pubmed	Lack of nitric oxide synthase depresses ion transporting enzyme function in cardiac muscle.	ATP2A1 ATP2A2	1.75e-05	4	60	2	12074580
Pubmed	Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart.	ATP2A1 ATP2A2	1.75e-05	4	60	2	9295312
Pubmed	Expression of sarco (endo) plasmic reticulum calcium ATPase (SERCA) system in normal mouse cardiovascular tissues, heart failure and atherosclerosis.	ATP2A1 ATP2A2	1.75e-05	4	60	2	25110346
Pubmed	SERCA1a can functionally substitute for SERCA2a in the heart.	ATP2A1 ATP2A2	1.75e-05	4	60	2	9887021
Pubmed	Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.	ATP2A1 ATP2A2	1.75e-05	4	60	2	10555147
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SYNRG MFHAS1 KCNH2 FANCI CSAD GRB10 WDFY3 CEP170B MAP3K5 FANCA	1.79e-05	1105	60	10	35748872
Pubmed	DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.	PIK3CG MAP3K5	2.92e-05	5	60	2	19903888
Pubmed	The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy.	ATP2A1 ATP2A2	2.92e-05	5	60	2	30299255
Pubmed	Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development.	CACNA1B ATP2A1 ATP2A2	3.94e-05	38	60	3	30786075
Pubmed	Organization, sequence, chromosomal localization, and promoter identification of the mouse orphan nuclear receptor Nurr1 gene.	SCN3A NR4A2	4.37e-05	6	60	2	9143501
Pubmed	Ebf factors and MyoD cooperate to regulate muscle relaxation via Atp2a1.	ATP2A1 ATP2A2	6.11e-05	7	60	2	24786561
Pubmed	The carboxyl terminus of FANCE recruits FANCD2 to the Fanconi Anemia (FA) E3 ligase complex to promote the FA DNA repair pathway.	FANCI FANCA	6.11e-05	7	60	2	24451376
Pubmed	Gene knockout studies of Ca2+-transporting ATPases.	ATP2A1 ATP2A2	8.14e-05	8	60	2	10951186
Pubmed	DNA polymerase POLN participates in cross-link repair and homologous recombination.	FANCI FANCA	8.14e-05	8	60	2	19995904
Pubmed	Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and beta-cell death.	ATP2A1 ATP2A2	8.14e-05	8	60	2	19033399
Pubmed	Early Developmental Disruption of Type 2 Deiodinase Pathway in Mouse Skeletal Muscle Does Not Impair Muscle Function.	ATP2A1 ATP2A2	8.14e-05	8	60	2	27967605
Pubmed	Mouse histamine N-methyltransferase: cDNA cloning, expression, gene cloning and chromosomal localization.	CACNA1B HNMT	8.14e-05	8	60	2	11475331
Pubmed	Sequential docking, molecular differentiation, and positioning of T-Tubule/SR junctions in developing mouse skeletal muscle.	ATP2A1 ATP2A2	8.14e-05	8	60	2	11784029
Pubmed	Widespread control of calcium signaling by a family of SERCA-inhibiting micropeptides.	ATP2A1 ATP2A2	8.14e-05	8	60	2	27923914
Pubmed	Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development.	CACNA1B KCNH2 SCN3A ATP2A2	1.00e-04	139	60	4	16985003
Pubmed	The Na(+)-K(+)-ATPase alpha2-subunit isoform modulates contractility in the perinatal mouse diaphragm.	ATP2A1 ATP2A2	1.05e-04	9	60	2	15253893
Pubmed	A micropeptide encoded by a putative long noncoding RNA regulates muscle performance.	ATP2A1 ATP2A2	1.05e-04	9	60	2	25640239
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	USP31 SYNRG LRPPRC GRB10 CEP170B PCM1 DOP1A FAM110B	1.12e-04	861	60	8	36931259
Pubmed	A novel conditional mouse model for Nkx2-5 reveals transcriptional regulation of cardiac ion channels.	KCNH2 ATP2A2	1.31e-04	10	60	2	26897459
Pubmed	The Polycomb-group gene Rae28 sustains Nkx2.5/Csx expression and is essential for cardiac morphogenesis.	ATP2A1 ATP2A2	1.59e-04	11	60	2	12122109
Pubmed	Forkhead transcription factor FoxF1 interacts with Fanconi anemia protein complexes to promote DNA damage response.	FANCI FANCA	1.59e-04	11	60	2	26625197
Pubmed	Role of FIP200 in cardiac and liver development and its regulation of TNFalpha and TSC-mTOR signaling pathways.	RB1CC1 MAP3K5	1.59e-04	11	60	2	17015619
Pubmed	Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.	LIPC DLST	1.59e-04	11	60	2	23144319
Pubmed	The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair.	FANCI FANCA	1.59e-04	11	60	2	19965384
Pubmed	Systematic Identification of Oncogenic EGFR Interaction Partners.	AMPH USP33	1.91e-04	12	60	2	27956147
Pubmed	Motor phenotypes and molecular networks associated with germline deficiency of Ciz1.	ZFHX4 NR4A2	1.91e-04	12	60	2	27163549
Pubmed	Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development.	NR4A2 GRB10 MYO16 AMIGO2	1.98e-04	166	60	4	19906978
Pubmed	Mechanism of Ubiquitination and Deubiquitination in the Fanconi Anemia Pathway.	FANCI FANCA	2.26e-04	13	60	2	27986371
Pubmed	Genetic mapping of the mouse genes encoding the voltage-sensitive calcium channel subunits.	CACNA1B SCN3A	2.63e-04	14	60	2	7490102
Pubmed	Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons.	NR4A2 GRB10	3.03e-04	15	60	2	19515692
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	CACNA1B STXBP5 ATP2A2 CEP170B PCM1	3.35e-04	347	60	5	17114649
Pubmed	Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice.	ZFHX4 WDFY3	3.46e-04	16	60	2	16096065
Pubmed	Differential physiological roles for BIN1 isoforms in skeletal muscle development, function and regeneration.	AMPH ATP2A1	3.46e-04	16	60	2	32994313
Pubmed	Dynamic regulation of sarcoplasmic reticulum Ca(2+) stores by stromal interaction molecule 1 and sarcolipin during muscle differentiation.	ATP2A1 ATP2A2	3.91e-04	17	60	2	22411552
Pubmed	Non conservation of function for the evolutionarily conserved prdm1 protein in the control of the slow twitch myogenic program in the mouse embryo.	ATP2A1 ATP2A2	4.40e-04	18	60	2	22522309
Pubmed	Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation.	CACNA1B ATP2A2 PRDM2 DOP1A	4.66e-04	208	60	4	33230847
Pubmed	Overexpression of TEAD-1 in transgenic mouse striated muscles produces a slower skeletal muscle contractile phenotype.	ATP2A1 ATP2A2	5.45e-04	20	60	2	18978355
Pubmed	Congenital heart defect causing mutation in Nkx2.5 displays in vivo functional deficit.	KCNH2 ATP2A1	6.02e-04	21	60	2	28302382
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	SYNRG PPP2R3A KLHL9 STXBP5 CEP170B PCM1 FAM110B	6.50e-04	853	60	7	28718761
Pubmed	Maternal exercise intergenerationally drives muscle-based thermogenesis via activation of apelin-AMPK signaling.	ATP2A1 ATP2A2	6.61e-04	22	60	2	35081489
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	USP31 STXBP5 GRB10 CEP170B USP33	6.90e-04	407	60	5	12693553
Pubmed	A comprehensive negative regulatory program controlled by Brn3b to ensure ganglion cell specification from multipotential retinal precursors.	ZFHX4 NR4A2	7.23e-04	23	60	2	18367606
Pubmed	Fanconi Anemia	FANCI FANCA	7.23e-04	23	60	2	20301575
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	CACNA1B SYNRG LRPPRC AMPH DLST ATP2A2 CEP170B PCM1	7.30e-04	1139	60	8	36417873
Pubmed	Loss of connectin novex-3 leads to heart dysfunction associated with impaired cardiomyocyte proliferation and abnormal nuclear mechanics.	ATP2A2 PCM1	8.56e-04	25	60	2	38877142
Pubmed	The DNA sequence of human chromosome 7.	AMPH KCNH2 PIK3CG GRB10 HBP1	9.87e-04	441	60	5	12853948
Pubmed	Complementary proteomics strategies capture an ataxin-1 interactome in Neuro-2a cells.	LRPPRC MFHAS1 DLST ATP2A1 ATP2A2 PCM1	9.96e-04	665	60	6	30457570
Pubmed	The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma.	NR2C1 ARNT	9.99e-04	27	60	2	26469385
Pubmed	DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.	NR2C1 FANCI INTS3 ATP2A2 FANCA	1.11e-03	453	60	5	29656893
Pubmed	Biology, structure and mechanism of P-type ATPases.	ATP2A1 ATP2A2	1.15e-03	29	60	2	15071553
Pubmed	The TIP60 Complex Is a Conserved Coactivator of HIF1A.	LRPPRC ARNT FANCI	1.19e-03	120	60	3	27320910
Pubmed	Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression.	LRPPRC PWP2 INTS3 ATP2A2	1.27e-03	272	60	4	31010829
Pubmed	Centronuclear myopathy in mice lacking a novel muscle-specific protein kinase transcriptionally regulated by MEF2.	ATP2A1 ATP2A2	1.32e-03	31	60	2	16140986
Pubmed	The MYO6 interactome reveals adaptor complexes coordinating early endosome and cytoskeletal dynamics.	SYNRG ZFYVE9 PCM1	1.34e-03	125	60	3	29467281
Pubmed	Protein-protein interactions between large proteins: two-hybrid screening using a functionally classified library composed of long cDNAs.	GRB10 TSPYL4 MYO16	1.49e-03	130	60	3	12421765
Pubmed	Mechanisms and Consequences of Dopamine Depletion-Induced Attenuation of the Spinophilin/Neurofilament Medium Interaction.	AMPH ATP2A2 MAP3K5	1.53e-03	131	60	3	28634551
Pubmed	LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.	KCNH2 ATP2A2	1.58e-03	34	60	2	26378152
Pubmed	Defining the human deubiquitinating enzyme interaction landscape.	LRPPRC KLHL9 PIK3CG FANCI PWP2 DLST USP33	1.68e-03	1005	60	7	19615732
GeneFamily	ATPases Ca2+ transporting	ATP2A1 ATP2A2	1.45e-04	9	37	2	1209
GeneFamily	Ring finger proteins\|Fanconi anemia complementation groups\|Protein phosphatase 1 regulatory subunits\|BRCA1 A complex\|BRCA1 B complex\|BRCA1 C complex	FANCI FANCA	7.56e-04	20	37	2	548
GeneFamily	Zinc fingers FYVE-type\|Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors	ZFYVE9 WDFY3	1.83e-03	31	37	2	81
GeneFamily	Nuclear hormone receptors	NR2C1 NR4A2	4.51e-03	49	37	2	71
GeneFamily	Ubiquitin specific peptidases	USP31 USP33	5.85e-03	56	37	2	366
Coexpression	GSE19941_LPS_VS_LPS_AND_IL10_STIM_IL10_KO_NFKBP50_KO_MACROPHAGE_UP	HTR1F PIK3CG STXBP5 FANCI HBP1 MYO16	5.18e-06	199	58	6	M8119
Coexpression	CAIRO_HEPATOBLASTOMA_CLASSES_UP	LRPPRC FANCI DLST TIMELESS RB1CC1 PCM1 SPDL1 FANCA	5.79e-05	612	58	8	M4772
Coexpression	GSE26488_HDAC7_KO_VS_VP16_TRANSGENIC_HDAC7_KO_DOUBLE_POSITIVE_THYMOCYTE_UP	CSAD HBP1 PRDM2 FAM110B AMIGO2	6.37e-05	190	58	5	M8190
Coexpression	GSE22033_WT_VS_PPARG_KO_MEF_UP	NR2C1 ZFHX4 SCN3A CEP170B MAP3K5	7.20e-05	195	58	5	M7694
Coexpression	GSE36476_YOUNG_VS_OLD_DONOR_MEMORY_CD4_TCELL_16H_TSST_ACT_UP	AMPH LIPC CCDC102B MYO16 FAM110B	7.38e-05	196	58	5	M5313
Coexpression	GSE36476_CTRL_VS_TSST_ACT_16H_MEMORY_CD4_TCELL_YOUNG_UP	NR4A2 HBP1 RB1CC1 TSPYL4 MAP3K5	7.74e-05	198	58	5	M5287
Coexpression	GSE3982_MAST_CELL_VS_TH2_UP	ZFYVE9 GRB10 HBP1 EXTL2 AMIGO2	7.74e-05	198	58	5	M5455
Coexpression	GSE1460_DP_THYMOCYTE_VS_NAIVE_CD4_TCELL_CORD_BLOOD_DN	AMPH PPP2R3A HTR1F GVINP1 GRB10	7.93e-05	199	58	5	M3460
Coexpression	GSE40274_LEF1_VS_FOXP3_AND_LEF1_TRANSDUCED_ACTIVATED_CD4_TCELL_DN	MFHAS1 PWP2 IL17RA TSPYL4 DOP1A	7.93e-05	199	58	5	M9159
Coexpression	GSE25123_WT_VS_PPARG_KO_MACROPHAGE_ROSIGLITAZONE_STIM_UP	PWP2 WDFY3 USP33 MAP3K5 FAM110B	8.12e-05	200	58	5	M7978
Coexpression	GSE21063_WT_VS_NFATC1_KO_BCELL_UP	USP31 NLRP12 PIK3CG SCN3A EXTL2	8.12e-05	200	58	5	M8260
Coexpression	GSE7460_TCONV_VS_TREG_LN_UP	MFHAS1 PIK3CG IL17RA TSPYL4 AMIGO2	8.12e-05	200	58	5	M5673
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBGABA	CACNA1B AMPH ZFHX4 STXBP5 CSAD SCN3A TSPYL4 DOP1A	1.51e-04	703	58	8	M39070
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Mucinous_Colon_Adenocarcinoma-10\|TCGA-Colorectal / Sample_Type by Project: Shred V9	NLRP12 AMPH EVC2 CCDC102B CD163	4.31e-06	179	60	5	cc079ba015326dccde955c5eafa3e4a2e40de192
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-myeloid-myeloid_monocytic-classical_monocyte\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	NLRP12 AMPH WDFY3 HNMT CD163	6.54e-06	195	60	5	580ed65b4152483b642a7e7dbdf00d03588c46f6
ToppCell	severe_influenza-NK_CD56bright\|severe_influenza / disease group, cell group and cell class (v2)	LIPC LCTL CCDC102B ATP2A1	5.98e-05	157	60	4	fabaf54429dd5a899f9192f0d42522109ca36b9b
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FANCI TIMELESS SPDL1 FANCA	7.25e-05	165	60	4	88681101d7cf60b99b8ace5d8c0944323b937306
ToppCell	facs-Marrow-Granulocytes-18m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLRP12 LRPPRC LCTL HNMT	7.59e-05	167	60	4	528493896aebe7d03d4b6ad2341b12927859e2e4
ToppCell	facs-Marrow-Granulocytes-18m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLRP12 LRPPRC LCTL HNMT	7.59e-05	167	60	4	a82e85caf79395baa48380786d9df32a86dfd1ce
ToppCell	droplet-Marrow-nan-3m-Myeloid-basophil\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NR2C1 GVINP1 NR4A2 TSPYL4	7.95e-05	169	60	4	5f5bec13208f4c3b6eacbba180c8a6402743b76e
ToppCell	10x5'-lymph-node_spleen-Hematopoietic_progenitors-Cycling_pre-Myeloid-2\|lymph-node_spleen / Manually curated celltypes from each tissue	NLRP12 WDFY3 HNMT CD163	8.70e-05	173	60	4	783b8fa08b9d8f597f251793eae164151662f1f9
ToppCell	COPD-Epithelial-PNEC\|Epithelial / Disease state, Lineage and Cell class	CACNA1B AMPH KCNH2 SCN3A	9.93e-05	179	60	4	988d0853c391da1e5004f73f3678047418d3f6d3
ToppCell	Monocytes-Donor_02\|World / lung cells shred on cell class, cell subclass, sample id	NLRP12 AMPH NR4A2 CD163	1.04e-04	181	60	4	d8b98c3d9bef026a0a35948219027f27718ffbee
ToppCell	10x5'v1-week_12-13-Mesenchymal_myocytic-stroma-muscle\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	AMPH LCTL ZFHX4 CEP170B	1.15e-04	186	60	4	fbc4ba4a7a8e5902a1b0add52ece0d6da85a8a5f
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CACNA1B KCNH2 SCN3A AMIGO2	1.15e-04	186	60	4	b45cce768e4bf91da194fd9660cab7520dfb15ac
ToppCell	10x5'-GI_large-bowel-Myeloid_Monocytic\|GI_large-bowel / Manually curated celltypes from each tissue	AMPH WDFY3 HNMT CD163	1.20e-04	188	60	4	d0045fdda757d191dabc7853f6a6e99c0e97d93d
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	PWP2 NR4A2 IFI44L CD163	1.20e-04	188	60	4	3f47395db7e6159fc95810545bad4b6e028464c5
ToppCell	10x5'-GI_large-bowel-Myeloid_Monocytic-Classical_monocytes\|GI_large-bowel / Manually curated celltypes from each tissue	AMPH WDFY3 HNMT CD163	1.20e-04	188	60	4	0bcf04aa47738f43c1a87dae5dc487738ee86f8c
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CACNA1B KCNH2 SCN3A AMIGO2	1.20e-04	188	60	4	c4c3b21ab723b0e9beff9ec84f8d68485f771528
ToppCell	cellseq-Immune-Hematopoietic-Granulocytic-Neutrophil\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NLRP12 PIK3CG STXBP5 IL17RA	1.22e-04	189	60	4	fedab592be1d6520325b8c1b659b0a4dc3f4fe4d
ToppCell	Monocytes-Donor_06\|World / lung cells shred on cell class, cell subclass, sample id	NLRP12 AMPH IL17RA CD163	1.22e-04	189	60	4	22d08c7dde697f385100f72e009eeac8d19d329d
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-A\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NR2C1 STXBP5 CD163 MAP3K5	1.25e-04	190	60	4	63018acb7ad80415e861643162abdc2e55968ee4
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	PWP2 NR4A2 IFI44L CD163	1.25e-04	190	60	4	4498705c5c1c7ba88a26fd2f412cf1aadd0f572a
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MFHAS1 CCDC102B MAP3K5 FAM110B	1.25e-04	190	60	4	0fea33f2dc1efa23aaa2da1c318482a52a313ff1
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	IFI44L RB1CC1 PCM1 PRDM2	1.27e-04	191	60	4	1ecd9849d14d5ebf3daf610e83fb50820cafd3ed
ToppCell	3'-GW_trimst-2-LargeIntestine-Mesenchymal-immature_mesenchymal_cell-cycling_stromal\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FANCI TIMELESS SPDL1 FANCA	1.27e-04	191	60	4	50854384fdaa0efa2e3227659d544ed09ac102f2
ToppCell	COVID-19-kidney-CNT\|kidney / Disease (COVID-19 only), tissue and cell type	PPP2R3A MFHAS1 SCN3A FAM110B	1.30e-04	192	60	4	d32ae226d95b4b6adb99d14b602be09b661d4cd9
ToppCell	H1299-infected\|H1299 / Cell line, Condition and Strain	CSAD AMIGO2 SPDL1 FANCA	1.30e-04	192	60	4	9cf8049bdc3e0f81ce69042beac72b08d8f38b4e
ToppCell	control-T/NK_proliferative\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	FANCI TIMELESS SPDL1 FANCA	1.33e-04	193	60	4	ecb4018a47d9a82bb999e0bc8b3dceabd97d1f0d
ToppCell	Control-Classical_Monocyte\|Control / Disease condition and Cell class	NLRP12 IL17RA HNMT CD163	1.35e-04	194	60	4	9e33e1b54b4114f9e6981819834bb796ed7192b5
ToppCell	Hippocampus-Neuronal\|Hippocampus / BrainAtlas - Mouse McCarroll V32	CACNA1B STXBP5 RB1CC1 CEP170B	1.35e-04	194	60	4	8aeb347b3024354c9505f4f0fddf0b843489dc6b
ToppCell	PBMC-Control-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_2\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NLRP12 IL17RA HNMT CD163	1.38e-04	195	60	4	0110b976f98561ecd2e20ff6e7e3960a401bb7c2
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-myeloid-myeloid_monocytic-intermediate_monocyte\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	AMPH WDFY3 HNMT CD163	1.38e-04	195	60	4	403d874198a7bde626b0d0b4efad8dbb34060761
ToppCell	Macrophages-Donor_03\|World / lung cells shred on cell class, cell subclass, sample id	IFI44L HNMT CD163 AMIGO2	1.38e-04	195	60	4	e48bf57e6da23fbb4637a02387155f825455c49f
ToppCell	PBMC-Control-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_2\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NLRP12 IL17RA HNMT CD163	1.38e-04	195	60	4	050fc59b328391d6e3ce23051764a842dcbb3144
ToppCell	Bronchial-NucSeq-Epithelial-Epi_airway_neuro-secretory-Neuroendocrine\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1B KCNH2 SCN3A FAM135B	1.41e-04	196	60	4	4bdc304c0c9d8bebe1a6a8a27e44acd1e8113725
ToppCell	Adult-Immune-monocyte-D122\|Adult / Lineage, Cell type, age group and donor	NLRP12 AMPH IL17RA CD163	1.41e-04	196	60	4	16b0acb6157534938ca83d4e909471e33a7d3c52
ToppCell	3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.0.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IFI44L HNMT CD163 AMIGO2	1.41e-04	196	60	4	a7291291931f9e5abd6a54349bc920a0ab68a4cb
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-myeloid-myeloid_monocytic\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	AMPH WDFY3 HNMT CD163	1.41e-04	196	60	4	f943519bff51c3094776fd45889dadf9062c8379
ToppCell	(0)_Myeloid-(000)_CD14+_Monocyte\|(0)_Myeloid / immune cells in Peripheral Blood (logTPM normalization)	NLRP12 NR4A2 IL17RA CD163	1.41e-04	196	60	4	e9718642ee2751c9d46a1b968547bdcb59cdfd30
ToppCell	COVID-granulo1-\|COVID / Condition, Cell_class and T cell subcluster	NLRP12 IL17RA HNMT CD163	1.44e-04	197	60	4	190392117dc6269a21983bd3e554066fd48acd5e
ToppCell	COVID-granulo1\|COVID / Condition, Cell_class and T cell subcluster	NLRP12 IL17RA HNMT CD163	1.44e-04	197	60	4	4cd774d9d5a6bf7729dc6b7bcd3ddfe3f3051ada
ToppCell	10x_3'_v3-thymus_(10x_3'_v3)-myeloid-myeloid_monocytic-monocyte\|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	AMPH WDFY3 HNMT CD163	1.44e-04	197	60	4	ec46aa307ce5774b4c0fcba64514f2d0cab3c4f9
ToppCell	Bronchial-10x5prime-Epithelial-Epi_airway_neuro-secretory-Neuroendocrine\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1B AMPH KCNH2 SCN3A	1.44e-04	197	60	4	3a0e97bfebe82f9687d518baaad7f20d0ffea8a1
ToppCell	COVID-19_Moderate-Classical_Monocyte\|COVID-19_Moderate / disease group, cell group and cell class	NLRP12 IL17RA HNMT CD163	1.44e-04	197	60	4	98d4107e457e7399a84439acd73bf8f59598971b
ToppCell	10x_3'_v3-thymus_(10x_3'_v3)-myeloid-myeloid_monocytic\|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	AMPH WDFY3 HNMT CD163	1.44e-04	197	60	4	b91016249b3585aa3536e96af18e4f1b1d2d5ce4
ToppCell	COVID-19_Severe-Classical_Monocyte\|World / disease group, cell group and cell class	IFI44L IL17RA WDFY3 CD163	1.44e-04	197	60	4	344801997b89bd81d8d5c3c872934de523233a8d
ToppCell	TCGA-Skin-Metastatic-Melanoma\|TCGA-Skin / Sample_Type by Project: Shred V9	PIK3CG CCDC102B PCM1 CD163	1.46e-04	198	60	4	af4fb9eb2295c7b90624b38ba25619aa15254efa
ToppCell	10x5'-lymph-node_spleen-Myeloid_Monocytic\|lymph-node_spleen / Manually curated celltypes from each tissue	NLRP12 WDFY3 HNMT CD163	1.46e-04	198	60	4	2541f1095ed91e6789cb888cf39a208b8107726a
ToppCell	TCGA-Skin-Metastatic\|TCGA-Skin / Sample_Type by Project: Shred V9	PIK3CG CCDC102B PCM1 CD163	1.46e-04	198	60	4	ad39cce004867f083f8da1954e0cf5a263815184
ToppCell	10x5'-lymph-node_spleen-Myeloid_Monocytic-Classical_monocytes\|lymph-node_spleen / Manually curated celltypes from each tissue	NLRP12 WDFY3 HNMT CD163	1.46e-04	198	60	4	934dacb67d71faa2f8732c39d7f8e64b0ee75396
ToppCell	5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	AMPH NR4A2 IL17RA CD163	1.46e-04	198	60	4	273a9e24438c31c1d3fc3ad71efbfafb54747476
ToppCell	3'_v3-lymph-node_spleen-Myeloid_Monocytic-Classical_monocytes\|lymph-node_spleen / Manually curated celltypes from each tissue	IL17RA WDFY3 HNMT CD163	1.46e-04	198	60	4	187a04d498f0b355cb11c81172721698818082d6
ToppCell	5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	AMPH NR4A2 IL17RA CD163	1.46e-04	198	60	4	9375a9fd31393709e1e3078f4b130e9e71a37c13
ToppCell	TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma\|TCGA-Skin / Sample_Type by Project: Shred V9	PIK3CG CCDC102B PCM1 CD163	1.46e-04	198	60	4	62cbf4b29e8af4983fb47a17f96da62682a5137e
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c13-MKI67-CCL5_l\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	FANCI TIMELESS SPDL1 FANCA	1.46e-04	198	60	4	6981cd5b1585c8ae6febdf0c4fb83067127f106c
ToppCell	3'_v3-lymph-node_spleen-Myeloid_Monocytic\|lymph-node_spleen / Manually curated celltypes from each tissue	IL17RA WDFY3 HNMT CD163	1.46e-04	198	60	4	065c8a9655d19f93dfdb453c78bbfe7d857caf3e
ToppCell	3'_v3-bone_marrow-Myeloid_Monocytic\|bone_marrow / Manually curated celltypes from each tissue	IL17RA WDFY3 HNMT CD163	1.49e-04	199	60	4	51a766f823a9d50a3b1d59d0df2f5241a6b44c2b
ToppCell	Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_alveolar-Macro_alv_dividing\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	FANCI TIMELESS CD163 DOP1A	1.49e-04	199	60	4	c6d59ed26eadd3c41acfe1b4d929270e00ea3e95
ToppCell	Bronchial-10x5prime-Immune_Myeloid-Macrophage_alveolar-Macro_alv_dividing\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	TIMELESS HNMT CD163 FANCA	1.49e-04	199	60	4	e1190b1c2d21fed313bb58e24d0e6365de6e6599
ToppCell	3'_v3-bone_marrow-Myeloid_Monocytic-Classical_monocytes\|bone_marrow / Manually curated celltypes from each tissue	IL17RA WDFY3 HNMT CD163	1.49e-04	199	60	4	93f25e8f22deb438c930c2e95e572dbd16503f71
ToppCell	mild-HLA-DR+_CD83+_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	IFI44L IL17RA WDFY3 CD163	1.52e-04	200	60	4	934c2efc780318c66d667ca75be0de350361d351
ToppCell	Sigmoid-(4)_Monocyte\|Sigmoid / shred on region, Cell_type, and subtype	AMPH WDFY3 HNMT CD163	1.52e-04	200	60	4	7f3920a0434d5199c6c8f0b3064a305bb0d87b60
ToppCell	Sigmoid-Monocyte-Monocyte\|Sigmoid / Region, Cell class and subclass	AMPH WDFY3 HNMT CD163	1.52e-04	200	60	4	010ca36970cb8894bdbca08779c0ecf56be22fc9
ToppCell	control-T/NK_proliferative\|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	FANCI TIMELESS SPDL1 FANCA	1.52e-04	200	60	4	1da366e35a05f73253629663eeea1fed4ebd7b52
ToppCell	Transverse-Dendritic_cell-cycling_DCs\|Dendritic_cell / Region, Cell class and subclass	FANCI HNMT CD163 SPDL1	1.52e-04	200	60	4	617a6a42f7b31eb3c45bdceaf55a591b6de7f154
ToppCell	control-HLA-DR-_S100A+_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NLRP12 IL17RA HNMT CD163	1.52e-04	200	60	4	107a0665fb20247511a430178effd7630a619488
ToppCell	Sigmoid-Monocyte\|Sigmoid / Region, Cell class and subclass	AMPH WDFY3 HNMT CD163	1.52e-04	200	60	4	c41bd6ec0f2262fce5cadb37a400d487e6662f49
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-immature_mesenchymal_cell-cycling_stromal\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FANCI TIMELESS SPDL1 FANCA	1.52e-04	200	60	4	43571c9284d4e41402a2d1eefc1efe2ce8476d4a
ToppCell	Sigmoid-(4)_Monocyte-(40)_Monocyte\|Sigmoid / shred on region, Cell_type, and subtype	AMPH WDFY3 HNMT CD163	1.52e-04	200	60	4	576c0a1098e6a934448705de3673ef798fcf1b26
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c10-MKI67-GZMK\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	FANCI TIMELESS GTF3C6 SPDL1	1.52e-04	200	60	4	83cc5f7e812896d97950afbc6bdc10c4eb2f507a
ToppCell	control-Neutrophil\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NLRP12 IL17RA HNMT CD163	1.52e-04	200	60	4	251ca08fab5cc2a4e280db6a6286a9ebaef3e61a
ToppCell	severe-CD163+_Monocytes_(Sample_ID1_d7)\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NLRP12 IFI44L WDFY3 CD163	1.52e-04	200	60	4	a3f22826f3d8f917ff0594bdadd93b60763bcaa2
ToppCell	severe-CD163+_Monocytes_(Sample_ID1_d7)\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NLRP12 IFI44L WDFY3 CD163	1.52e-04	200	60	4	4943fe826d5fcc3dfeb8b99a7415848f3fecc994
ToppCell	control-HLA-DR-_S100A+_Monocyte\|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NLRP12 IL17RA WDFY3 CD163	1.52e-04	200	60	4	9e3e13a68bc1110fa000ec2d80f4c654ddbce17e
Drug	Betaxolol hydrochloride [63659-19-8]; Down 200; 11.6uM; MCF7; HT_HG-U133A	PPP2R3A ARNT ZFYVE9 GRB10 IL17RA WDFY3 HNMT	7.35e-07	196	59	7	3208_DN
Drug	1-2q	NR2C1 NLRP12 LIPC MFHAS1 HBP1 TIMELESS ATP2A2 AMIGO2	7.74e-07	289	59	8	CID000011820
Drug	Trimethoprim [738-70-5]; Up 200; 13.8uM; MCF7; HT_HG-U133A	KCNH2 NR4A2 GRB10 PCM1 PRDM2 DOP1A FANCA	7.87e-07	198	59	7	4701_UP
Drug	Proparacaine hydrochloride [5875-06-9]; Down 200; 12uM; MCF7; HT_HG-U133A	ARNT KCNH2 ATP2A2 PCM1 PRDM2 MAP3K5 FAM110B	8.14e-07	199	59	7	6492_DN
Drug	halofantrine	KCNH2 RB1CC1 AMIGO2	4.64e-06	13	59	3	CID000037392
Drug	Pizotifen malate [5189-11-7]; Up 200; 9.4uM; PC3; HT_HG-U133A	AMPH MFHAS1 NR4A2 ATP2A1 FAM110B AMIGO2	8.36e-06	185	59	6	5072_UP
Drug	Terfenadine [50679-08-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A	NR2C1 ZFYVE9 KCNH2 IL17RA HNMT PCM1	1.00e-05	191	59	6	2227_DN
Drug	Metformin hydrochloride [1115-70-4]; Up 200; 24.2uM; PC3; HT_HG-U133A	NR2C1 ARNT IFI44L WDFY3 HNMT FAM110B	1.06e-05	193	59	6	1816_UP
Drug	Sertaconazole nitrate [99592-39-9]; Down 200; 8uM; HL60; HT_HG-U133A	ARNT ZFYVE9 NR4A2 WDFY3 CEP170B PCM1	1.10e-05	194	59	6	6128_DN
Drug	Methionine sulfoximine (L) [15985-39-4]; Down 200; 22.2uM; HL60; HT_HG-U133A	NR2C1 ARNT GDPD3 WDFY3 PCM1 PRDM2	1.13e-05	195	59	6	2470_DN
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Up 200; 5.8uM; PC3; HT_HG-U133A	ARNT ZFYVE9 KCNH2 GDPD3 NR4A2 IFI44L	1.16e-05	196	59	6	4508_UP
Drug	Cefepime hydrochloride [123171-59-5]; Down 200; 7.4uM; MCF7; HT_HG-U133A	PPP2R3A WDFY3 ATP2A2 PCM1 MAP3K5 FANCA	1.20e-05	197	59	6	6237_DN
Drug	Mefexamide hydrochloride [3413-64-7]; Up 200; 12.6uM; MCF7; HT_HG-U133A	PPP2R3A ARNT KCNH2 HBP1 WDFY3 FAM110B	1.20e-05	197	59	6	7478_UP
Drug	3-CPs	NLRP12 LIPC ATP2A2	2.82e-05	23	59	3	CID000062739
Drug	AC1L1G3W	NLRP12 TIMELESS ATP2A1 HNMT ATP2A2 MAP3K5	3.39e-05	237	59	6	CID000003514
Drug	EUK-8	ATP2A1 ATP2A2 MAP3K5	3.65e-05	25	59	3	CID000171249
Drug	XeC compound	CACNA1B PIK3CG ATP2A1 ATP2A2	6.72e-05	84	59	4	CID000005701
Drug	Syrosingopine [84-36-6]; Up 200; 6uM; MCF7; HT_HG-U133A	ZFHX4 KCNH2 GRB10 HBP1 PRDM2	9.82e-05	178	59	5	2753_UP
Drug	APETx1, Anthopleura elegantissima	KCNH2 SCN3A	9.84e-05	6	59	2	ctd:C475726
Drug	felodipine; Up 200; 10uM; MCF7; HT_HG-U133A_EA	ZFYVE9 KCNH2 NR4A2 HNMT PCM1	1.09e-04	182	59	5	848_UP
Drug	wortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A	PPP2R3A ARNT KCNH2 HBP1 HNMT	1.12e-04	183	59	5	1668_UP
Drug	Alsterpaullone; Down 200; 10uM; PC3; HT_HG-U133A	SYNRG KLHL9 RB1CC1 PRDM2 AMIGO2	1.15e-04	184	59	5	7056_DN
Drug	Rapamycin; Up 200; 0.1uM; PC3; HT_HG-U133A	ZFYVE9 KCNH2 HBP1 RB1CC1 AMIGO2	1.18e-04	185	59	5	4445_UP
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	PPP2R3A ARNT HBP1 EXTL2 RB1CC1	1.21e-04	186	59	5	1664_UP
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	KCNH2 NR4A2 HBP1 RB1CC1 HNMT	1.21e-04	186	59	5	4460_UP
Drug	Apigenin [520-36-5]; Down 200; 14.8uM; MCF7; HT_HG-U133A	NR2C1 PPP2R3A WDFY3 MAP3K5 AMIGO2	1.27e-04	188	59	5	3257_DN
Drug	rapamycin, Streptomyces hygroscepicus; Up 200; 0.1uM; PC3; HT_HG-U133A	PPP2R3A ARNT GDPD3 HBP1 IL17RA	1.27e-04	188	59	5	5980_UP
Drug	wortmannin; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA	PPP2R3A HBP1 RB1CC1 HNMT PCM1	1.30e-04	189	59	5	911_UP
Drug	pioglitazone HCl; Up 200; 10uM; PC3; HT_HG-U133A	PPP2R3A ARNT IL17RA PRDM2 AMIGO2	1.37e-04	191	59	5	5977_UP
Drug	Digitoxigenin [143-62-4]; Down 200; 10.6uM; PC3; HT_HG-U133A	MFHAS1 IL17RA WDFY3 HNMT MAP3K5	1.37e-04	191	59	5	4217_DN
Drug	simendan	KCNH2 ATP2A2	1.37e-04	7	59	2	ctd:C076731
Drug	Ranolazine	KCNH2 ATP2A2	1.37e-04	7	59	2	ctd:D000069458
Drug	Rapamycin; Up 200; 0.1uM; PC3; HT_HG-U133A	NR4A2 HBP1 RB1CC1 PRDM2 AMIGO2	1.40e-04	192	59	5	1221_UP
Drug	Acetohexamide [968-81-0]; Up 200; 12.4uM; PC3; HT_HG-U133A	NR2C1 PPP2R3A ZFYVE9 IFI44L PRDM2	1.40e-04	192	59	5	1829_UP
Drug	Berberine chloride [633-65-8]; Down 200; 10.8uM; HL60; HG-U133A	TSPYL4 ATP2A2 CEP170B PCM1 FANCA	1.40e-04	192	59	5	1778_DN
Drug	(-)-depudecin; Up 200; 1uM; MCF7; HT_HG-U133A_EA	SYNRG NR2C1 ARNT GDPD3 WDFY3	1.44e-04	193	59	5	982_UP
Drug	Carcinine [56897-53-1]; Down 200; 22uM; MCF7; HT_HG-U133A	SYNRG ZFYVE9 HNMT PCM1 DOP1A	1.44e-04	193	59	5	3242_DN
Drug	rapamycin, Streptomyces hygroscepicus; Up 200; 0.1uM; PC3; HT_HG-U133A	ARNT NR4A2 HBP1 HNMT AMIGO2	1.44e-04	193	59	5	5932_UP
Drug	Diphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; PC3; HT_HG-U133A	ARNT KLHL9 ZFYVE9 HNMT AMIGO2	1.44e-04	193	59	5	1830_UP
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	NR4A2 HBP1 IFI44L HNMT CEP170B	1.47e-04	194	59	5	1239_UP
Drug	Benzydamine hydrochloride [132-69-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A	NR2C1 ARNT KCNH2 IL17RA HNMT	1.47e-04	194	59	5	3169_DN
Drug	Iopanoic acid [96-83-3]; Down 200; 7uM; MCF7; HT_HG-U133A	PPP2R3A ARNT KCNH2 CEP170B PCM1	1.47e-04	194	59	5	3527_DN
Drug	Zardaverine [101975-10-4]; Up 200; 15uM; MCF7; HT_HG-U133A	PPP2R3A ARNT WDFY3 PRDM2 FANCA	1.47e-04	194	59	5	7347_UP
Drug	Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A	NR2C1 ARNT ZFYVE9 IL17RA EXTL2	1.47e-04	194	59	5	3274_DN
Drug	Amoxicillin [26787-78-0]; Up 200; 11uM; MCF7; HT_HG-U133A	ARNT ZFYVE9 ATP2A2 DOP1A FANCA	1.51e-04	195	59	5	5385_UP
Drug	Bicuculline (+) [485-49-4]; Up 200; 10.8uM; MCF7; HT_HG-U133A	ARNT GRB10 WDFY3 HNMT PRDM2	1.51e-04	195	59	5	2796_UP
Drug	Gabapentin [60142-96-3]; Up 200; 23.4uM; MCF7; HT_HG-U133A	ZFYVE9 KCNH2 NR4A2 IL17RA ATP2A2	1.51e-04	195	59	5	3472_UP
Drug	Nafronyl oxalate [3200-06-4]; Up 200; 8.4uM; MCF7; HT_HG-U133A	PPP2R3A ARNT KLHL9 CSAD HBP1	1.51e-04	195	59	5	5287_UP
Drug	Promazine hydrochloride [53-60-1]; Down 200; 12.4uM; HL60; HT_HG-U133A	NR2C1 ARNT GDPD3 NR4A2 WDFY3	1.51e-04	195	59	5	2173_DN
Drug	Cefamandole sodium salt [30034-03-8]; Up 200; 8.2uM; PC3; HT_HG-U133A	ARNT MFHAS1 NR4A2 IL17RA WDFY3	1.51e-04	195	59	5	7394_UP
Drug	Leflunomide [75706-12-6]; Up 200; 14.8uM; PC3; HT_HG-U133A	ZFYVE9 TIMELESS IFI44L PRDM2 MAP3K5	1.51e-04	195	59	5	5884_UP
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; MCF7; HT_HG-U133A	ARNT ZFHX4 KCNH2 ATP2A1 HNMT	1.51e-04	195	59	5	4369_DN
Drug	Tadjakonine [11087-94-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	ARNT KCNH2 TIMELESS HNMT PCM1	1.51e-04	195	59	5	2820_DN
Drug	Lithocholic acid [434-13-9]; Down 200; 10.6uM; MCF7; HT_HG-U133A	ARNT HTR1F WDFY3 ATP2A2 DOP1A	1.51e-04	195	59	5	4373_DN
Drug	Piretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A	ARNT NR4A2 EXTL2 PCM1 FANCA	1.51e-04	195	59	5	6828_DN
Drug	carbidine	HTR1F ATP2A1 ATP2A2	1.53e-04	40	59	3	CID000065684
Drug	Pentamidine isethionate [140-64-7]; Down 200; 6.8uM; HL60; HT_HG-U133A	NR2C1 WDFY3 ATP2A2 PCM1 AMIGO2	1.54e-04	196	59	5	2473_DN
Drug	Atracurium besylate [64228-81-5]; Down 200; 3.2uM; MCF7; HT_HG-U133A	ARNT NR4A2 GRB10 IL17RA HNMT	1.54e-04	196	59	5	7477_DN
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	ARNT ZFYVE9 WDFY3 HNMT FAM110B	1.54e-04	196	59	5	7356_DN
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; MCF7; HT_HG-U133A	SYNRG TIMELESS IL17RA HNMT CEP170B	1.54e-04	196	59	5	3844_DN
Drug	Neomycin sulfate [1405-10-3]; Down 200; 4.2uM; MCF7; HT_HG-U133A	PPP2R3A ARNT HNMT PCM1 FANCA	1.54e-04	196	59	5	2229_DN
Drug	Parbendazole [14255-87-9]; Down 200; 16.2uM; MCF7; HT_HG-U133A	NR2C1 KCNH2 IL17RA PCM1 FAM110B	1.54e-04	196	59	5	3881_DN
Drug	Phenformin hydrochloride [834-28-6]; Down 200; 16.6uM; MCF7; HT_HG-U133A	PPP2R3A NR4A2 GRB10 MAP3K5 FAM110B	1.54e-04	196	59	5	4747_DN
Drug	(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Up 200; 12.2uM; MCF7; HT_HG-U133A	AMPH ARNT GRB10 HNMT PRDM2	1.54e-04	196	59	5	5533_UP
Drug	Clobetasol propionate [25122-46-7]; Down 200; 8.6uM; MCF7; HT_HG-U133A	ARNT CEP170B MAP3K5 FAM110B FANCA	1.58e-04	197	59	5	6095_DN
Drug	Pyrazinamide [ 98-96-4]; Up 200; 32.4uM; MCF7; HT_HG-U133A	ARNT HTR1F ZFYVE9 KCNH2 IL17RA	1.58e-04	197	59	5	2839_UP
Drug	Hexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	NR4A2 GRB10 TIMELESS PRDM2 FAM110B	1.58e-04	197	59	5	6252_UP
Drug	Ketoprofen [22071-15-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	PPP2R3A TIMELESS WDFY3 PRDM2 FAM110B	1.58e-04	197	59	5	4751_DN
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A	ARNT KLHL9 WDFY3 RB1CC1 HNMT	1.58e-04	197	59	5	1800_UP
Drug	Atracurium besylate [64228-81-5]; Up 200; 3.2uM; PC3; HT_HG-U133A	NR2C1 ZFYVE9 IFI44L WDFY3 HNMT	1.58e-04	197	59	5	1824_UP
Drug	Alfaxalone [23930-19-0]; Up 200; 12uM; MCF7; HT_HG-U133A	HTR1F ZFYVE9 KCNH2 PCM1 FANCA	1.58e-04	197	59	5	6514_UP
Drug	Propafenone hydrochloride [34183-22-7]; Down 200; 10.6uM; MCF7; HT_HG-U133A	PPP2R3A KCNH2 IL17RA MAP3K5 DOP1A	1.58e-04	197	59	5	2871_DN
Drug	Chloropyramine hydrochloride [6170-42-9]; Up 200; 12.2uM; HL60; HT_HG-U133A	AMPH ZFYVE9 GDPD3 TIMELESS CEP170B	1.58e-04	197	59	5	3011_UP
Drug	LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A	PPP2R3A ZFYVE9 TIMELESS WDFY3 PCM1	1.58e-04	197	59	5	1641_UP
Drug	Metformin hydrochloride [1115-70-4]; Up 200; 24.2uM; HL60; HT_HG-U133A	ARNT PWP2 IL17RA TSPYL4 MAP3K5	1.58e-04	197	59	5	1858_UP
Drug	aspirin, USP; Up 200; 100uM; MCF7; HT_HG-U133A	NR2C1 PPP2R3A MFHAS1 EXTL2 HNMT	1.58e-04	197	59	5	1629_UP
Drug	Etanidazole [22668-01-5]; Up 200; 18.6uM; MCF7; HT_HG-U133A	PPP2R3A ZFYVE9 HNMT MAP3K5 FANCA	1.58e-04	197	59	5	6211_UP
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; HL60; HT_HG-U133A	ARNT MFHAS1 NR4A2 ATP2A2 PCM1	1.58e-04	197	59	5	2171_DN
Drug	Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Down 200; 21uM; MCF7; HT_HG-U133A	SYNRG NR2C1 KCNH2 WDFY3 RB1CC1	1.58e-04	197	59	5	3338_DN
Drug	pioglitazone HCl; Down 200; 10uM; MCF7; HT_HG-U133A	ARNT GRB10 TIMELESS HNMT FAM110B	1.58e-04	197	59	5	7523_DN
Drug	Gliclazide [21187-98-4]; Down 200; 12.4uM; MCF7; HT_HG-U133A	NR2C1 PPP2R3A WDFY3 ATP2A2 MAP3K5	1.58e-04	197	59	5	2870_DN
Drug	Bupropion hydrochloride [31677-93-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A	ARNT KLHL9 HNMT ATP2A2 PCM1	1.58e-04	197	59	5	3180_DN
Drug	Eucatropine hydrochloride [536-93-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	PPP2R3A ARNT HTR1F KCNH2 PCM1	1.58e-04	197	59	5	3935_DN
Drug	Flunarizine dihydrochloride [30484-77-6]; Up 200; 8.4uM; MCF7; HT_HG-U133A	NR2C1 KCNH2 GRB10 PCM1 MAP3K5	1.62e-04	198	59	5	7013_UP
Drug	Trioxsalen [3902-71-4]; Up 200; 17.6uM; MCF7; HT_HG-U133A	NR2C1 ZFYVE9 NR4A2 HNMT PRDM2	1.62e-04	198	59	5	6216_UP
Drug	vinblastine sulfate; Down 200; 0.1uM; MCF7; HT_HG-U133A	PPP2R3A ZFYVE9 NR4A2 WDFY3 PCM1	1.62e-04	198	59	5	7517_DN
Drug	Guaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A	PPP2R3A ARNT PCM1 FAM110B FANCA	1.62e-04	198	59	5	3897_DN
Drug	15(S)-15-methyl Prostaglandin E2; Down 200; 10uM; MCF7; HT_HG-U133A	ZFYVE9 KCNH2 TIMELESS HNMT FAM110B	1.62e-04	198	59	5	7489_DN
Drug	Isoniazid [54-85-3]; Down 200; 29.2uM; MCF7; HT_HG-U133A	ARNT KLHL9 GRB10 IL17RA PRDM2	1.62e-04	198	59	5	2246_DN
Drug	Cotinine (-) [486-56-6]; Down 200; 22.6uM; MCF7; HT_HG-U133A	ZFHX4 KCNH2 WDFY3 MAP3K5 FANCA	1.62e-04	198	59	5	5246_DN
Drug	(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; PC3; HT_HG-U133A	MFHAS1 NR4A2 IL17RA WDFY3 PCM1	1.62e-04	198	59	5	4259_DN
Drug	Tremorine dihydrochloride [300-68-5]; Down 200; 15uM; HL60; HG-U133A	KLHL9 PWP2 TIMELESS RB1CC1 HNMT	1.62e-04	198	59	5	1579_DN
Drug	Nicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; PC3; HT_HG-U133A	PPP2R3A ZFYVE9 TIMELESS HNMT PCM1	1.62e-04	198	59	5	6297_DN
Drug	Dipyrone [5907-38-0]; Down 200; 12uM; MCF7; HT_HG-U133A	PPP2R3A IL17RA HNMT PCM1 MAP3K5	1.62e-04	198	59	5	6030_DN
Drug	Zalcitabine [7481-89-2]; Down 200; 19uM; PC3; HT_HG-U133A	MFHAS1 IL17RA WDFY3 PCM1 MAP3K5	1.62e-04	198	59	5	4215_DN
Drug	Phenelzine sulfate [156-51-4]; Up 200; 17uM; MCF7; HT_HG-U133A	AMPH ZFYVE9 ZFHX4 HNMT FANCA	1.62e-04	198	59	5	2319_UP
Drug	Nisoxetine hydrochloride [57754-86-6]; Down 200; 13uM; MCF7; HT_HG-U133A	NR2C1 PPP2R3A ARNT HNMT ATP2A2	1.66e-04	199	59	5	6496_DN
Drug	Nifedipine [21829-25-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A	NR2C1 PPP2R3A ZFYVE9 NR4A2 GRB10	1.66e-04	199	59	5	6006_DN
Drug	DNA-PK Inhibitor III; Down 200; 1uM; PC3; HT_HG-U133A	HTR1F NR4A2 IFI44L ATP2A2 PCM1	1.66e-04	199	59	5	7548_DN
Drug	Sulfinpyrazone [57-96-5]; Down 200; 9.8uM; PC3; HT_HG-U133A	ARNT MFHAS1 GDPD3 NR4A2 WDFY3	1.66e-04	199	59	5	5753_DN
Disease	malate dehydrogenase, cytoplasmic measurement	NLRP12 CD163	3.93e-06	2	59	2	EFO_0020551
Disease	Schizophrenia	CACNA1B HTR1F KCNH2 NR4A2 GRB10 RB1CC1 ATP2A2 MYO16 PCM1 CD163	9.11e-06	883	59	10	C0036341
Disease	Brody myopathy (implicated_via_orthology)	ATP2A1 ATP2A2	1.18e-05	3	59	2	DOID:0050692 (implicated_via_orthology)
Disease	caudate nucleus measurement, functional brain measurement, response to reward	CCDC102B MYO16 FAM135B	1.16e-04	47	59	3	EFO_0007849, EFO_0008387, EFO_0008396
Disease	Fanconi anemia (is_implicated_in)	FANCI FANCA	1.75e-04	10	59	2	DOID:13636 (is_implicated_in)
Disease	Fanconi anemia	FANCI FANCA	3.52e-04	14	59	2	cv:C0015625
Disease	leucine measurement	PPP2R3A LIPC RB1CC1	4.28e-04	73	59	3	EFO_0009770
Disease	Bone marrow hypocellularity	FANCI FANCA	5.89e-04	18	59	2	C1855710
Disease	ovulation	FANCI FANCA	6.58e-04	19	59	2	GO_0030728
Disease	metabolic syndrome	PPP2R3A ARNT LIPC KCNH2	6.97e-04	200	59	4	EFO_0000195
Disease	Fanconi Anemia	FANCI FANCA	1.14e-03	25	59	2	C0015625
Disease	monocyte count	NLRP12 PIK3CG STXBP5 HBP1 DLST IL17RA MYO16 MAP3K5 FANCA	1.17e-03	1320	59	9	EFO_0005091
Disease	Pancytopenia	FANCI FANCA	1.24e-03	26	59	2	C0030312
Disease	Acute monocytic leukemia	FANCI FANCA	1.24e-03	26	59	2	C0023465
Disease	Endogenous Hyperinsulinism	CD163 FANCA	1.24e-03	26	59	2	C1257963
Disease	Exogenous Hyperinsulinism	CD163 FANCA	1.24e-03	26	59	2	C1257964
Disease	Compensatory Hyperinsulinemia	CD163 FANCA	1.24e-03	26	59	2	C1257965
Disease	Congestive heart failure	PIK3CG ATP2A1 ATP2A2	1.41e-03	110	59	3	C0018802
Disease	Heart failure	PIK3CG ATP2A1 ATP2A2	1.41e-03	110	59	3	C0018801
Disease	Left-Sided Heart Failure	PIK3CG ATP2A1 ATP2A2	1.41e-03	110	59	3	C0023212
Disease	Heart Failure, Right-Sided	PIK3CG ATP2A1 ATP2A2	1.41e-03	110	59	3	C0235527
Disease	Heart Decompensation	PIK3CG ATP2A1 ATP2A2	1.41e-03	110	59	3	C1961112
Disease	Myocardial Failure	PIK3CG ATP2A1 ATP2A2	1.41e-03	110	59	3	C1959583
Disease	Hyperinsulinism	CD163 FANCA	1.44e-03	28	59	2	C0020459
Disease	Miller Dieker syndrome	FANCI FANCA	1.54e-03	29	59	2	C0265219
Disease	Abnormality of radial ray	FANCI FANCA	1.99e-03	33	59	2	C4228778

Protein segments in the cluster

Peptide	Gene	Start	Entry
NSKFLRCDDDQMSND	ARNT	56	P27540
NMDSVAADCLTNVTN	CEACAM18	151	A8MTB9
MDFLNSSDQNLTSEE	HTR1F	1	P30939
CDELSFLLDEMQTAQ	GVINP1	716	Q7Z2Y8
LQTLMNACSQASDFS	DOP1A	791	Q5JWR5
QVLLLQDSFMNCSDS	AMIGO2	271	Q86SJ2
LNSRDFDQNMNDSCE	CEP170B	1401	Q9Y4F5
MLSCLSNQACDEQAN	CACNA1B	1661	Q00975
TIEMCNALNSLSENQ	ATP2A1	906	O14983
TDQSMICNLAESEQA	AMPH	416	P49418
LSNDDTSLCEFQEMQ	NR2C1	301	P13056
CQMQEDNSSFSLLLD	INTS3	661	Q68E01
AAIMANLEDCSNSYQ	RB1CC1	151	Q8TDY2
NSVANETFCLEIMDS	FANCI	576	Q9NVI1
LMLSLFEQSLSCQAQ	IL17RA	751	Q96F46
FCELASLESLMLDNN	MFHAS1	246	Q9Y4C4
FLVNTMNSCLHSQDE	MYO16	751	Q9Y6X6
MLQLCLFTITDQENN	AQP7B	186	A0A075B734
DDCSEVLQDNFLNMS	IFI44L	361	Q53G44
DSLSQVSQFMACEEL	KCNH2	1106	Q12809
LIDDTQNCDDIAMNF	EXTL2	236	Q9UBQ6
CQYITSDDLTQMLDN	HNMT	196	P50135
DFSVSICQTLMQDQQ	PCM1	1011	Q15154
ALETCSINNQMLAAE	LCTL	516	Q6UWM7
SLNMDNLQDTLEAAS	KLHL9	116	Q9P2J3
LENMEADTFATLCSQ	EVC2	1106	Q86UK5
QQRMTFCSENTDDLL	LIPC	461	P11150
QENGCLSDSDMFSQA	LRPPRC	496	P42704
NSMAQRSDLLELDCQ	GDPD3	61	Q7L5L3
NLTSMFLQNFSEEDL	PPP2R3A	196	Q06190
AQNTCAMLTTFNEID	DLST	241	P36957
IEMCNALNSLSENQS	ATP2A2	906	P16615
AQAFESCQLDSMVTA	FANCA	416	O15360
CLQLAEQMTQSDAQD	C1orf112	221	Q9NSG2
NSALTCADMDFLLNE	CSAD	471	Q9Y600
LNFRSASMISSDCEQ	FAM110B	306	Q8TC76
VNDMNASLESLYSAC	GRB10	56	Q13322
SGMNDSLELLQCNEN	HBP1	26	O60381
ETTSCQMTNCEQDLF	KRTAP27-1	56	Q3LI81
ETLSQLCSELQMLNN	FAM135B	281	Q49AJ0
DNCMVNSNLSFREDL	FAM135B	446	Q49AJ0
SCLNADDLDLMNSSE	CD163	1101	Q86VB7
ESCEHTDQFQLSSQM	CCDC102B	166	Q68D86
TNNNTSNCDVIEMES	PRDM2	576	Q13029
SMANNIILYCDTNSD	MAP3K5	176	Q99683
SNLQNMNIDISAFSC	NR4A2	491	P43354
EEIQMNDSSNLSCEQ	GTF3C6	166	Q969F1
PLNLADLDMFSSVNC	SYNRG	611	Q9UMZ2
FANERCLQLSESENM	SPDL1	411	Q96EA4
NMFDISDVNNLSDCQ	SCN3A	1371	Q9NY46
LTYSQETCENLQEML	STXBP5	1016	Q5T5C0
LLSENCDSFVSQNMI	C12orf40	291	Q86WS4
LTMQLLDCNFSDENV	PIK3CG	626	P48736
QLQCCAQNSELSMDS	TIMELESS	566	Q9UNS1
QMDALSADLTQLCQQ	ZFHX4	2056	Q86UP3
LSTCVQNMQQSDDLS	WDFY3	261	Q8IZQ1
SCNLSLDAMEEFLNR	PWP2	646	Q15269
NNCMDSLEAIDQELS	TSPYL4	201	Q9UJ04
TCFMNATLQCLSNTE	USP31	136	Q70CQ4
SLMDAFSCSLDNENR	ZFYVE9	176	O95405
SRCFSEDNNETTMLI	USP33	336	Q8TEY7
NCDSSGMNLNNISEL	ZNF487	166	B1APH4
NQSATECSMQDLIFS	NLRP12	256	P59046